ANDA 212721, held by Astral. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 212721 (Cefepime Hydrochloride), held by Astral, was first approved by FDA on Jul 21, 2020, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2020 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Discontinued |
| Aug 9, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 21, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters